BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis & Investment Frameworks
BioCryst Pharmaceuticals, Inc. (BCRX) stock analysis on Invetso. Review BioCryst Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
BioCryst Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
BioCryst Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $2.06B
- Revenue: $874.84M
- P/E Ratio: 7.83
- ROE: 101.55%
- ROIC: -88.96%
- Dividend Yield: N/A
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes BioCryst Pharmaceuticals, Inc. (BCRX) across the following frameworks:
- BioCryst Pharmaceuticals, Inc. 10Y Growth Potential
- BioCryst Pharmaceuticals, Inc. Scenario Analysis
- BioCryst Pharmaceuticals, Inc. Risks & Opportunities
- BioCryst Pharmaceuticals, Inc. Economic Moat
- BioCryst Pharmaceuticals, Inc. Business Model
- BioCryst Pharmaceuticals, Inc. Management
- BioCryst Pharmaceuticals, Inc. SWOT Analysis
- BioCryst Pharmaceuticals, Inc. Porter's 5 Forces
- BioCryst Pharmaceuticals, Inc. PESTLE Analysis
- BioCryst Pharmaceuticals, Inc. ESG Analysis